ArticleBMC complementary and alternative medicine2019
Bitter gourd (Momordica charantia) possess developmental toxicity as revealed by screening the seeds and fruit extracts in zebrafish embryos.
Article in BMC complementary and alternative medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 70 citations in OpenAlex.
- A screening strategy for identifying the developmental and reproductive toxicity potential of botanicals.Pharmaceutical biology · 2026Review
- Article
- A traditional herbal remedy in liver diseases:Hepatology forum · 2026Review
- Review
- Toxicological screening of jambolan hydroalcoholic extract (Toxicology reports · 2025Article
- Toxicity Assessment ofInternational journal of environmental research and public health · 2022Article
- Review
- Review
- Evaluation of acute and sub-chronic toxicity of bitter melon seed extract in Wistar rats.Toxicology reports · 2022Article
- Co-electrospun nanofibrous mats loaded with bitter gourd (Momordica charantia) extract as the wound dressing materials: in vitro and in vivo study.BMC complementary medicine and therapies · 2021Article
- Systematic Review of Medicinal Plants Used for Treatment of Diabetes in Human Clinical Trials: An ASEAN Perspective.Evidence-based complementary and alternative medicine : eCAM · 2021Review
- The Effect ofEvidence-based complementary and alternative medicine : eCAM · 2021Review
- Zebrafish as a Successful Animal Model for Screening Toxicity of Medicinal Plants.Plants (Basel, Switzerland) · 2020Review
- Cytotoxic Evaluation and Anti-Angiogenic Effects of Two Furano-Sesquiterpenoids fromMolecules (Basel, Switzerland) · 2020Article
- Zebrafish: An emerging whole-organism screening tool in safety pharmacology.Indian journal of pharmacologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundBitter gourd (Momordica charantia) has attracted the focus of researchers owing to its excellent anti-diabetic action. The beneficial effect of Momordica charantia on heart has been reported by in vitro and in vivo studies. However the developmental toxicity or potential risk of M. charantia on fetus heart development is largely unknown. Hence this study was designed to find out the developmental toxicity of M. charantia using zebrafish (Danio rerio) embryos.
methodsThe crude extracts were prepared from fruit and seeds of M. charantia. The Zebrafish embryos were exposed to serial dilution of each of the crude extract. The biologically active fractions were fractionated by C18 column using high pressure liquid chromatography. Fourier-transform infrared spectroscopy and gas chromatography coupled with mass spectrophotometry was done to identify chemical constituents in fruit and seed extract of M. charantia.
resultsThe seed extract of M. charantia was lethal with LD
conclusionThe teratogenicity of seeds extract and cardiac toxicity by the fruit extract of M. charantia warned that the supplementation made from the fruit and seeds of M. charantia should be used with much care in pregnant diabetic patients to avoid possible damage to developing fetus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.